Janus Kinase Inhibitors: all 1,428 studies that test it

Page 11 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingNCT05371964Phase 1
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• Baricitinib for Cutaneous DermatomyositisWithdrawnNCT05361109Phase 2
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedNCT05335447Phase 1
• Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCompletedNCT05330858Phase 1
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial SpondyloarthritisStatus unknownNCT05324631Phase 3
• Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic EventsCompletedNCT05313620Phase 4
• A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic SclerosisActive, not recruitingNCT05300932Phase 4
• Role of Tofacitinib in Vitiligo PatientsStatus unknownNCT05293119Early Phase 1
• Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19Status unknownNCT05279391Not applicable
• Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedNCT05272683Phase 1
• Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.Status unknownNCT05246293Phase 2
• BARIcitinib Cognitive Emotional and Neural signaTuRETerminatedNCT05238896Phase 4
• Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseaseCompletedNCT05237388Phase 2
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2WithdrawnNCT05233410Phase 3
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1WithdrawnNCT05219864Phase 3
• A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompletedNCT05192369Phase 1
• Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.Status unknownNCT05153200Phase 4
• Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation SyndromeStatus unknownNCT05137496Phase 3
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedNCT05127174Phase 1
• An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail PsoriasisCompletedNCT05124080Early Phase 1
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated CorticosteroidsTerminatedNCT05123040Phase 1/2
• Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus MethotrexateStatus unknownNCT05121298Phase 3
• Study of Ruxolitinib for Acute and Chronic Graft Versus Host DiseaseCompletedNCT05121142Phase 1
• Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsCompletedNCT05104723Phase 1/2
• TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedNCT05091723Phase 1
• Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateStatus unknownNCT05090410Phase 3
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
• Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's SyndromeStatus unknownNCT05087589Phase 2
• Tocilizumab Versus Baricitinib in Patients With Severe COVID-19CompletedNCT05082714Not applicable
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• JAK Inhibition in Food AllergyCompletedNCT05069831Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707CompletedNCT05068466Phase 1
• Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedNCT05063110Phase 2
• Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Status unknownNCT05056558Phase 3
• A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedNCT05051553Phase 1
• A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleCompletedNCT05050279Early Phase 1
• Study of Ruxolitinib Cream in Children With Atopic DermatitisCompletedNCT05034822Phase 1
• Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDStatus unknownNCT05021276Phase 4
• A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisCompletedNCT05020652Phase 2
• Efficacy and Safety of Baricitinib in Sjogren's SyndromeCompletedNCT05016297Phase 2
• A Study of JNJ-64251330 in Participants With Familial Adenomatous PolyposisCompletedNCT05014360Phase 1
• Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)CompletedNCT05006768Phase 1
• Single and Multiple Ascending Dose Study of KN-002CompletedNCT05006521Phase 1
• A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Phase 4
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3CompletedNCT04985955Phase 1
• A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04976270Phase 1
• Effect of Tofacitinib in Treating ANCA-associated VasculitisCompletedNCT04973033Not applicable
• Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnNCT04970719Phase 3
• The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis PatientsStatus unknownNCT04966884Phase 4
• Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPAStatus unknownNCT04944524Phase 4
• A Study of TQ05105 in Patients With Chronic Graft Versus Host DiseaseActive, not recruitingNCT04944043Phase 1/2
• A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)TerminatedNCT04941404Phase 1/2
• The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid ArthritisStatus unknownNCT04927000Phase 4
• Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis ManagementActive, not recruitingNCT04925973Phase 2
• Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaCompletedNCT04919642Phase 2
• A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsCompletedNCT04916756Phase 1/2
• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantTerminatedNCT04908735Phase 2
• Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 2
• EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform TrialTerminatedNCT04891133Phase 2/3
• Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingNCT04859946Phase 2
• Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult SubjectsCompletedNCT04843540Phase 1
• Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell TransplantationCompletedNCT04838704Not applicable
• Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoCompletedNCT04822584Phase 2
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
• Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib CreamCompletedNCT04807751Phase 1
• Tofacitinib as a GC Sparing Agent for Polymyalgia RheumaticaCompletedNCT04799262Phase 2
• Baricitinib in New-onset Type 1 DiabetesCompletedNCT04774224Phase 2
• A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of AsthmaCompletedNCT04769869Phase 1
• Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK StudyTerminatedNCT04768504Phase 2
• Efficacy and Safety of Tofacitinib in Patients With COVID-19 PneumoniaCompletedNCT04750317Phase 2
• Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult SubjectsCompletedNCT04743414Phase 1
• A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
• Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedNCT04736927Phase 1
• Study on the Bioavailability of SHR0302 in Healthy SubjectsCompletedNCT04712838Phase 1
• Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy VolunteersCompletedNCT04705922Phase 1
• A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT04702464Phase 1
• Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownNCT04693026Phase 3
• Effect of BMS-986165 on the Blood Levels of MetforminCompletedNCT04671953Phase 1
• PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCTCompletedNCT04669210Phase 2
• A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in BrazilWithdrawnNCT04666675Phase 3
• A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
• PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTSCompletedNCT04634565Phase 1
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisActive, not recruitingNCT04624230Phase 3
• A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT04594928Phase 1
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male ParticipantsCompletedNCT04591262Phase 1
• Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsCompletedNCT04587713Phase 1
• Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedNCT04581954Phase 1/2
• Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release FormulationsCompletedNCT04580797Phase 1
• A Study of JNJ-64251330 in Healthy ParticipantsCompletedNCT04552197Phase 1
• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisActive, not recruitingNCT04551131Phase 1/2
• A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04536961Phase 1
• A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)Active, not recruitingNCT04520269Phase 1/2
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
• Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA PatientsCompletedNCT04485325Phase 4
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483700Phase 3
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483687Phase 3
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing SpondylitisCompletedNCT04481139Phase 2/3

← Janus Kinase Inhibitors overview